Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dade improved VRSA test:

This article was originally published in Clinica

Executive Summary

Dade Behring has received US FDA 510(k) clearance to market an enhanced version of its automated method for detecting vancomycin-resistant Staphylococcus aureus (VRSA). The Deerfield, Illinois company has developed an improved formulation of vancomycin to detect VRSA on its MicroScan dried gram-positive, overnight, antimicrobial susceptibility test panels. Dade, which has nearly 60 MicroScan panels of tests, with up-to-date antibiotics including overnight, rapid and specialty panels, said it was in the process of incorporating the new formulation of vancomycin into the entire product line of MicroScan dried gram-positive, overnight, panels sold globally. The new formulation is anticipated to be available in all of the existing configurations by the autumn of 2005.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT055666

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel